BAE-SYSTEMS
16.12.2022 10:02:34 CET | Business Wire | Press release
Sweden, Germany, and the United Kingdom have reached an agreement with BAE Systems to purchase 436 BvS10 all-terrain vehicles. The joint procurement, worth $760 million, is in support of Arctic operations for the Collaborative All-Terrain Vehicle (CATV) program.
BAE Systems’ military all-terrain vehicles are designed for operations in the harshest and most remote environments and this agreement signals the Company’s position as the defense industry’s leader for these capabilities.
“We‘re seeing increased interest from numerous countries for the extreme mobility capabilities offered by the BvS10 and its unarmored sister vehicle, Beowulf,” said Tommy Gustafsson-Rask, managing director of BAE Systems Hägglunds, which manufactures the vehicles in Örnsköldsvik, Sweden. “Sweden, Germany, and the United Kingdom will be getting an excellent return on their investment in these highly capable vehicles for decades to come. This further demonstrates the strong relationship between BAE Systems and our customers to deliver these critical capabilities.”
The three-nation acquisition will deliver the 436 vehicles beginning in 2024, with 236 BvS10s going to the Swedish Defense Materiel Administration (FMV), 140 to the German Federal Ministry of Defence (BAAINBw), and 60 to the United Kingdom Ministry of Defence (MoD). The vehicles are based on the latest version of the BvS10 currently operated by Sweden, and will include variants for troop transport, logistics, medical evacuation, recovery, and command and control.
The CATV program includes a framework agreement that could lead to the purchase of more vehicles by the three nations, keeping the BvS10, the world’s leading all-terrain vehicle, in production for many years to come. Sweden is the lead nation and has established a joint procurement office to lead the effort with representatives from all three nations.
This acquisition follows Sweden’s order last year of an additional 127 BvS10 all-terrain vehicles for its existing fleet. In parallel to this agreement, Sweden is also procuring an additional 40 BvS10s in a separate contract valued at approximately $50 million.
The BvS10 and Beowulf are the world leaders when it comes to all-terrain solutions. Their articulated mobility systems provide optimal maneuverability across varying terrains so they can traverse snow, ice, rock, sand, mud or swamps, as well as steep mountain environments. The vehicles’ amphibious feature also allow them to swim in flooded areas or coastal waters.
The vehicles can deliver personnel and supplies to sustain strategic, tactical, and operational mobility.
BvS10’s unprecedented mobility is based on terrain accessible North Atlantic Treaty Organization (NATO) standards. Its modular design allows it to be reconfigured for varying missions and can be delivered in multiple variants that include carrying personnel, command and control, ambulance, vehicle repair and recovery, logistics support, situational awareness, and a weapons carrier with additional mortar capability.
BvS10 is currently operated by Austria, France, the Netherlands, Sweden, and the United Kingdom. BAE Systems’ Beowulf, the unarmored variant of the BvS10, won the U.S. Army’s competition for its Cold Weather All-Terrain Vehicle (CATV) program in August. The U.S. Army will receive 110 vehicles over a five-year period.
Issued by:
BAE Systems, Inc.
www.baesystems.com
@BAESystemsInc
For associated imagery, please visit: https://baesys.resourcespace.com/?c=16201&k=d788ec24d8
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221216005114/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 14:40:00 CEST | Press release
Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa
ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 14:30:00 CEST | Press release
ParaScript’s AI-powered document intelligence technology integrates with Stakk’s SaaS platform to provide regulated organizations with a stronger defense against AI-driven digital identity fraud.Complementary technologies establish digital trust by continuously assessing identity, documents, behavior and context, making explainable decisions in milliseconds.Combined businesses serve more than 300 enterprise customers and processes more than 110 billion digital interactions annually across the U.S., Europe, the Middle East and Australia. ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document
SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 14:04:00 CEST | Press release
Awards expand deployment of SLB's integrated well construction model across Saudi Arabia’s oil and gas reservoirs Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every as
Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 14:03:00 CEST | Press release
Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 13:00:00 CEST | Press release
-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect-- Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077)-- Favorable safety and tolerability profile across both doses-- Detailed results to be presented at upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in November-- Conference call and webcast to be held today at 8:00 a.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
